This is especially the case for Kras mutations, which appear to be uncommon in the TCGA-HNC cohort (0.2%; 1 of 510 patients), but were found to be mutated in as high as 15% (1643/10,945 patients) of advanced/metastatic solid tumors and 1.07% (2/186 patients) in metastatic cancer annotated as HNC in the MSK-IMPACT cohort from the Memorial Sloan Kettering (MSK) Cancer Center [60]. The gene discussed is KRAS; the disease is cancer.